178+ M
SHL Medical autoinjectors reach patients worldwide in a year.
And we are growing capacity to reach more patients year by year.
About us
We are the pioneering leader in self-injection solutions, dedicated to enabling patients’ independence in their healthcare journey.
Where independence begins
SHL Medical is the pioneering leader in designing, developing, and manufacturing self-injection solutions such as autoinjectors, pen injectors, and innovative specialty delivery systems for large-volume and high-viscosity formulations.
By partnering with leading pharma and biotech companies, we will continue to develop and supply products and services in order to support, engage, and oversee patients whose quality of life relies on innovative self-treatment therapies. This we do with one purpose in mind: Enabling patients' independence.
SHL Medical in numbers
Some of our milestones
0 1 2 3 4 5 6 7 8 9 0
0 1 2 3 4 5 6 7 8 9 0
0 1 2 3 4 5 6 7 8 9 0
0 1 2 3 4 5 6 7 8 9 0
The journey begins
Roger Samuelsson and Martin Jelf establishes Scandinavian Health Limited (SHL Group).
1996
Launch of first autoinjector
The PenInject 2.25’s success inspires Roger’s vision of SHL as a
world-leading autoinjector solutions provider
In-house automation and assembly capabilities are established
2004
Design centers are founded in the US and Sweden
2007
On-site tooling capabilities are established - now with 48-cavity molds
Commercial launch of SHL’s first DAI® project
Commercial launch of SHL’s first DAI® project
The DAI becomes one of the most popular autoinjector formats on the market and lays the foundation for SHL’s success, supporting the modernization of self-injection treatment
Launch of Molly® autoinjector
The pre-configured Molly supports SHL's pharma partners in minimizing initial investments while maximizing development speed, later evolving into a modular platform with increased flexibility in design, development, and production.
Launch of final assembly, labeling, and packaging services in the US
New facility highlights SHL’s vertically integrated approach to drug delivery services, offering streamlined operations from product design to final delivery.
2,000-employee milestone
SHL sees several years of rapid employee growth, surpassing 2,000 people and signifying its arrival as a large-scale enterprise.
2016
Modularized fully automatic assembly and test equipment is introduced
Commercial launch of NIT®
Featuring a pre-installed needle, the groundbreaking Needle Isolation Technology radically simplifies how patients handle cartridge-based
injectors.
2018-19
Inauguration of Liufu site in Taiwan
SHL opens new combined building with modern office space with advanced manufacturing capacities
Inauguration of Liufu site in Taiwan - HQ in Switzerland opens
SHL opens new combined building with modern office space with advanced manufacturing capacities.
Switzerland headquarters is opened.
First Innovation Zed commercial partnership
- SHL acquires Weibel CDS as part of its expanding portfolio in innovative packaging technology and delivery systems.
-
First Innovation Zed commercial partnership
Insulin pen add-on device InsulCheck Connect marks the first commercialization of an SHL add-on device for any injector, highlighting our ability to expand our portfolio. The device will later go on to win the 2021 Good Design Award
-
2021/2022
As part of our global footprint strategy, SHL launched plans for new manufacturing sites in Zug and USA, respectively. Through closer proximity with customers, the new sites signify our efforts to lessen global carbon footprint.
Grand Opening of SHL Medical North Charleston
SHL opens its new fully automatized manufacturing facility in South Carolina, enhancing the company's US presence and solidifying its leadership in large-scale autoinjector production.
1.5 billion autoinjectors shipped
SHL Medical has reached a historic milestone, enabling patients’ independence 1.5 billion times through our self-injection solutions worldwide. This achievement reflects decades of teamwork, innovation, and trust, as well as the confidence our pharmaceutical and biotech partners place in us. With 1.5 billion autoinjectors shipped globally, we celebrate not only the scale of our impact, but also the shared commitment that continues to drive innovation in drug delivery and improve the lives of millions of patients around the world.
2000
2006
2010
2011
2013
2017
2018
2020
2025
![[.png] Snippet-B-Molly-G2.2-300dpi-20260205](https://cdn.bfldr.com/DTG6CG68/at/s8wfsvcbv3b5qht2cnk3m7p/Snippet-B-Molly-G22-300dpi-20260205.png?width=150&height=200&fit=crop&auto=webp&format=webp)
2025
![[.png] Snippet-B-Molly-G2.2-300dpi-20260205](https://cdn.bfldr.com/DTG6CG68/at/s8wfsvcbv3b5qht2cnk3m7p/Snippet-B-Molly-G22-300dpi-20260205.png?width=343&height=428&fit=crop&auto=webp&format=webp)
Built for sustainable growth
We have embarked on a journey to embed sustainability into how we operate, innovate, and grow, turning ambition into measurable action that supports long‑term value. Guided by our 2030 Sustainability Strategy, we focus on real progress: expanding patient access while reducing emissions, integrating circular design into our products, increasing renewable energy use, and strengthening ethical practices across our supply chain.
This is not about commitments on paper, but about implementation across our business, enabling patient independence, building operational resilience, and creating tangible, lasting impact for patients, partners, and society.
![[.png] 2026 SHL-Medical Gold-Medal](https://cdn.bfldr.com/DTG6CG68/at/rnm7p57ff5zs8z73tqmg5v/SHL_MEDICAL_AG_GROUP_EV_Recognition_3_7.png?width=480&height=480&fit=crop&auto=webp&format=webp)
Get to know our teams
Get in touch
For questions, ideas, partnership inquiries, or further requests, please don't hesitate to reach out. We will get back to you.
Call us
Mon-Fri from 8:00AM-5:00PM (GMT+2)
+41 41 368 00 00
Visit us
You can find our office HQ at
Gubelstrasse 22
6300 Zug, Switzerland